{"id":"NCT02974153","sponsor":"Alder Biopharmaceuticals, Inc.","briefTitle":"Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine","officialTitle":"A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2017-11","completion":"2018-04","firstPosted":"2016-11-28","resultsPosted":"2020-06-09","lastUpdate":"2020-06-09"},"enrollment":1121,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"PREVENTION"},"conditions":["Migraine Disorders"],"interventions":[{"type":"BIOLOGICAL","name":"ALD403 (Eptinezumab)","otherNames":["Eptinezumab-jjmr","Vyepti"]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"ALD403 (Eptinezumab) Dose Level 1","type":"EXPERIMENTAL"},{"label":"ALD403 (Eptinezumab) Dose Level 2","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.","primaryOutcome":{"measure":"Change From Baseline in Monthly Migraine Days","timeFrame":"Week 1-12","effectByArm":[{"arm":"300 mg ALD403","deltaMin":-8.2,"sd":null},{"arm":"100 mg ALD403","deltaMin":-7.7,"sd":null},{"arm":"Placebo","deltaMin":-5.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":144,"countries":["United States","Belgium","Czechia","Denmark","Georgia","Germany","Hungary","Italy","Russia","Slovakia","Spain","Ukraine","United Kingdom"]},"refs":{"pmids":["39666143","37378754","36284281","36068494","35436857","35332807","35302389","35189811","35131090","35130836","34823467","33781209","33023473","32209650"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":350},"commonTop":["Nasopharyngitis","Upper respiratory tract infection"]}}